Development of a reminiscence therapy online platform with machine learning to increase engagement with people living with dementia and their care partners

项目总结 近600万美国人患有阿尔茨海默病(AD)或与AD相关的痴呆症，而这一数字 受影响个人的数量正在迅速增长。症状包括认知障碍，导致学习困难。 进行日常活动，并随之而来对他人的功能依赖。AD的进步性和 ADRD可能会导致需要专业和家庭照顾者提供更多程度的护理。非- 药物干预积极影响认知、情绪和其他行为和心理。 痴呆症的症状，以及一项行之有效的干预措施，生活故事工作(使用书面和口头生活 病史)，是一种有效的技术，可以在患有AD和 阿德勒。然而，对于照顾者来说，制作有用的生活故事材料是一项耗时的任务。要克服 这一障碍，LifeBio Inc.正在开发一种回忆治疗平台-LifeBio Memory yTM-带着一种新颖的 基于机器学习的应用程序，将语音转换为文本并生成生活故事作为 互动工具，培养痴呆症患者及其家人和照顾者之间的沟通。 LifeBio Memory yTM平台应用程序将提取和存储个人的故事、照片和视频，并 最终为患者提供个性化的护理点怀旧治疗练习。在前期工作中 支持这一直接到第二阶段的提议，LifeBio Inc.与本杰明·罗斯老龄研究所合作 在疗养院进行的一项初步研究显示， 生命生物公司S干预的参与者并透露，大多数参与者认为 他们的生活故事对照顾者很重要，而照顾者也报告了与以下方面的积极经历 干预对照看的影响。在这个项目中，我们将：1)开发 现有的LifeBio计划，并对12个现有或以前的原型进行焦点小组评估 LifeBio用户，20名熟悉LifeBio的痴呆症护理专业人员和6名患有早期痴呆症的老年人 帮助在整个研究过程中保持以人为中心的做法；2)最终确定LifeBio记忆 产品，其中将包括开发一个自动记录和处理个人生活的系统 故事。3)对40名护理专业人员和160名痴呆症患者进行完整的保真度测试 在辅助生活环境中照顾两个人。这个直接转到第二阶段计划的产品，LifeBio Memory™将是一种新颖、可扩展且易于实施的解决方案，通过它，护理人员和医疗保健人员 提供者可以为AD患者和AD相关痴呆患者提供以人为中心的护理。

PROJECT SUMMARY Almost 6 million Americans are living with Alzheimer’s disease (AD) or AD-related dementias, and the number of affected individuals is rapidly growing. Symptoms include impaired cognition, resulting in difficulty in performing daily activities and consequent functional dependence on others. The progressive nature of AD and ADRD can result in increasing degrees of care required from professional and family caregivers. Non- pharmacologic interventions positively influence cognition, mood, and other behavioral and psychological symptoms of dementia, and one well-established intervention, life story work (the use of written and oral life histories), serves as an effective technique that can elicit conversation and memories in those with AD and ADRD. However, generating useful life story materials is a time-consuming task for caregivers. To overcome this barrier, LifeBio Inc. is developing a reminiscence therapy platform —LifeBio MemoryTM— with a novel machine-learning-based application that converts speech to text and generates life stories to serve as an interactive tool to cultivate communication between people living with dementia and their family and caregivers. The LifeBio MemoryTM platform application will elicit and store individuals’ stories, photos, and videos and ultimately deliver personalized, point-of-care reminiscence therapy exercises for patients. In preliminary work supporting this Direct-to-Phase II proposal, LifeBio Inc. partnered with the Benjamin Rose Institute on Aging to conduct a pilot study in nursing homes, which showed a significant decrease in depressive symptoms among participants in LifeBio Inc.’s intervention and revealed that the majority of participants considered knowledge of their life story to be important for caregivers, while caregivers also reported positive experiences in relation to the impact of the intervention on caregiving. In this project we will: 1) Develop prototype enhancements of the existing LifeBio program and conduct focus group evaluations of these prototypes with 12 existing or former LifeBio users, 20 dementia care professionals familiar with LifeBio and 6 older adults with early-stage dementia to help maintain person-centered practices throughout the research process; 2) Finalize the LifeBio Memory product, which will include the development of a system to automatically record and process individuals’ life stories. 3) Conduct a full-scale fidelity trial of the complete package with 40 care professionals and 160 dementia care dyads across within an assisted living setting. The product of this Direct-to-Phase II proposal, LifeBio Memory™, will be a novel, scalable, and easily implemented solution through which caregivers and healthcare providers can offer person-centered care to people living with AD and AD-related dementias.